Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)

PHASE1RecruitingINTERVENTIONAL
Enrollment

6

Participants

Timeline

Start Date

April 15, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

May 30, 2027

Conditions
Amyotrophic Lateral SclerosisALS
Interventions
DEVICE

Next Generation Dome Helmet Focused Ultrasound

Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening.

DRUG

Intravenous immunoglobulin (IVIG), 10% solution for infusion

"Two doses of IVIg will be administered 2 weeks apart. The first dose at Week 0 will be a standalone administration. The second dose at Week 2 will be combined with Next Generation Dome Helmet (NGDH) Focused Ultrasound (FUS) blood brain barrier (BBB) opening. Cohort I will receive 0.2g/kg of IVIg at each dose. Cohort II will receive 0.4g/kg of IVIg at each dose.~Privigen® IVIg comes in vials containing 10% active ingredient. It is supplied in 2.5 g (25 mL bottle), 5 g (50 mL bottle), 10 g (100 mL bottle), 20 g (200 mL bottle) or 40 g (400 mL bottle). The IVIg dose will be determined based on the patient's ideal body weight."

DRUG

Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension

DEFINITY® Perflutren Injectable Microbubbles is an ultrasound contrast imaging agent that will be used for blood brain barrier opening during focused ultrasound. These microbubbles will be injected during the focused ultrasound procedure on the day of the second IVIg dose.

Trial Locations (1)

M4N 3M5

RECRUITING

Sunnybrook Health Sciences Centre, Toronto

All Listed Sponsors
collaborator

Focused Ultrasound Foundation

OTHER

lead

Sunnybrook Health Sciences Centre

OTHER